engleski

Positive HER3 could be a marker of poor response to neoadjuvant dual anti-HER2 therapy in breast cancer

Breast cancer patients with over expressed human epidermal growth factor receptor 2 (HER2) recive dual anti-HER2 blockade with trastuzumab and pertuzumab in the neoadjuvant therapy. According to published literature, HER3 can mediate resistance to anti-HER2 therapy. The aim was to search for predictive factors of anti-HER2 neoadjuvant therapy. Poorer response to anti-HER2 therapy in HER3 positive breast cancer patients suggests a possibility for a new treatment option with directed anti-HER3 therapy.

Breast cancer, human epidermal growth factor receptor 2 (HER2) , neoadjuvant therapy, HER3

16th St. Gallen International Breast Cancer Conference